Ovarian cancer is one of the common tumors of female reproductive organs, ranking third in incidence after cervical cancer and uterine body cancer, and accounting for about 4% of all malignant tumors in women. Immunological examination is a new way to diagnose ovarian cancer and is currently a more ideal method to detect tumor markers. The sensitivity and specificity of ovarian malignant tumor markers cannot meet the needs of early diagnosis. They are mostly used to detect changes in the disease during and/or after treatment, to provide a basis for evaluating the efficacy and timely detection of tumor recurrence, so that effective treatment measures can be taken without losing time to improve the survival rate. 1.AFP: Whether AFP is elevated or not depends on whether the tumor tissue has endodermal sinus tumor components. It has specific value for ovarian endodermal sinus tumor (ovarian cystic tumor) or is meaningful for immature teratoma or mixed asexual cell tumor with yolk sac components. In case of recurrence or metastasis of tumor, even if there are tiny tumor foci, AFP will be elevated again, which is more sensitive than other examination methods. 2.Cancer antigen 125 (CA125). 3.Lactate dehydrogenase (LDH): LDH isoenzyme profile has certain significance for the diagnosis of malignant tumor. 4.Human chorionic gonadotropin (HCG): Measurement of serum β-HCG of patients can help diagnose ovarian choriocarcinoma and germ cell tumors with choriocarcinoma components, such as ovarian pure asexual cell tumors. It can also accurately reflect the number of cancer cells, so it can also be used as an indicator to observe the change of disease and the effect of anti-cancer treatment. 5.Sialic acid (SA): The dynamic observation of SA can help to change the treatment plan in time. 6.Cancer embryonic antigen (CEA): Currently, there are two methods to detect CEA, one is to determine blood CEA by radioimmunodiagnostic method and the other is to detect CEA of cancer tissue by immunohistochemistry method. The clinical results of these two tests are related to the tissue type of tumor, clinical stage and grading, therapeutic effect and whether there is metastasis and recurrence after treatment.